Radiomics and molecular analysis: Bridging the gap for predicting hepatocellular carcinoma prognosis DOI
Chun‐Han Cheng, Wen‐Rui Hao,

Tzu-Hurng Cheng

et al.

World Journal of Clinical Cases, Journal Year: 2024, Volume and Issue: 13(4)

Published: Nov. 13, 2024

This editorial examines a recent study that used radiomics based on computed tomography (CT) to predict the expression of fibroblast-related gene enhancer zeste homolog 2 (EZH2 ) and its correlation with survival patients hepatocellular carcinoma (HCC). By integrating molecular analysis, presented strategy for accurately predicting EZH2 from CT scans. The findings demonstrated strong link between model, expression, patient prognosis. noninvasive approach provides valuable insights into therapeutic management HCC.

Language: Английский

EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2 DOI Creative Commons

Yongwei Lai,

Xu Han,

Bo Xie

et al.

Cancer Science, Journal Year: 2024, Volume and Issue: 115(7), P. 2220 - 2234

Published: April 16, 2024

Enhancing sensitivity to sorafenib can significantly extend the duration of resistance it, offering substantial benefits for treating patients with hepatocellular carcinoma (HCC). However, role ferroptosis in influencing within HCC remains pivotal. The enhancer zeste homolog 2 (EZH2) plays a significant promoting malignant progression HCC, yet relationship between ferroptosis, sensitivity, and EZH2 is not entirely clear. Bioinformatic analysis indicates elevated expression predicting an unfavorable prognosis. Overexpressing drive cell proliferation while simultaneously reducing ferroptosis. Further reveals that amplifies modification H3K27 me3, thereby TFR2 expression. This results decreased RNA polymerase II binding promoter region, leading reduced Knocking down cells. In sorafenib-resistant HepG2(HepG2-SR) cells, increased. Moreover, combining tazemetostat-an inhibitor-with demonstrates synergistic ferroptosis-promoting effects HepG2-SR conclusion, our study illustrates how epigenetically regulates through suppressing combination tazemetostat exhibits superior anticancer therapy sensitizes cells sorafenib, shedding new light on delaying ameliorating resistance.

Language: Английский

Citations

13
Ferroptosis in Cancer: Epigenetic Control and Therapeutic Opportunities DOI Creative Commons

Roberta Veglia Tranchese,

Sabrina Battista, Laura Cerchia

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(11), P. 1443 - 1443

Published: Nov. 13, 2024

Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a critical pathway in cancer biology. This review delves into the epigenetic mechanisms that modulate ferroptosis cells, focusing on how DNA methylation, histone modifications, and non-coding RNAs influence expression function essential genes involved this process. By unraveling complex interplay between these ferroptosis, article sheds light novel gene targets functional insights could pave way for innovative treatments to enhance therapeutic efficacy overcome resistance therapy.

Language: Английский

Citations

7
Development of a sodium hyaluronate-enriched therapeutic formulation with stevia glycoside and mogroside V for the comprehensive management of diabetes and its complications DOI
Pengyu Lei, Hou‐Yong Yu, Tao Jiang

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 293, P. 139487 - 139487

Published: Jan. 5, 2025

Language: Английский

Citations

1
Epigenetic and Post-Translational Modifications in Ferroptosis Regulation and Hepatocellular Carcinoma: New Frontiers in Therapeutic Targeting DOI

Soheil Bolandi,

Samaneh Dodge,

Zahra Zahed

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155991 - 155991

Published: April 1, 2025

Language: Английский

Citations

1
Targeting cell death mechanisms: the potential of autophagy and ferroptosis in hepatocellular carcinoma therapy DOI Creative Commons
Beibei Liu,

Ling Liu,

Yang Liu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 9, 2024

Ferroptosis is a type of cell death that plays remarkable role in the growth and advancement malignancies including hepatocellular carcinoma (HCC). Non-coding RNAs (ncRNAs) have considerable impact on HCC by functioning as either oncogenes or suppressors. Recent research has demonstrated non-coding ability to control ferroptosis cells, hence impacting tumors resistance these cells drugs. Autophagy mechanism conserved throughout evolution maintaining balance body under normal settings. Nevertheless, occurrence dysregulation autophagy evident progression various human disorders, specifically cancer. dual roles cancer, potentially influencing both survival death. prevalent kind liver genetic mutations changes molecular pathways might worsen its advancement. The subject debate, it capacity repress promote tumor growth. activation can apoptosis, proliferation glucose metabolism, facilitate spread through EMT. Inhibiting hinder enhance respond treatment. regulated several signaling pathways, such STAT3, Wnt, miRNAs, lncRNAs, circRNAs. Utilizing anticancer drugs target may advantageous implications for efficacy cancer

Language: Английский

Citations

6
Ferroptosis: insight into the treatment of hepatocellular carcinoma DOI Creative Commons

Chuanjie Liao,

Youwu He, Xingju Luo

et al.

Cancer Cell International, Journal Year: 2024, Volume and Issue: 24(1)

Published: Nov. 13, 2024

Hepatocellular carcinoma (HCC) is one of the most common malignances in world, with high morbidity and mortality. Due to hidden onset symptoms, there are huge obstacles early diagnosis, recurrence, metastasis drug resistance. Although great strides have been made treatment HCC, effective options still limited achieving longer survival for patients remains urgent. Ferroptosis a novel type programmed cell death that mainly caused by iron-dependent oxidative damage. With further investigations, ferroptosis has proved be associated occurrence development various tumors. This article reviews regulatory mechanism signal transduction pathways ferroptosis, investigates complex relationship between autophagy, sorafenib resistance immunotherapy involved providing new ideas directions HCC.

Language: Английский

Citations

5
MCM4 potentiates evasion of hepatocellular carcinoma from sorafenib-induced ferroptosis through Nrf2 signaling pathway DOI

Xujin Liu,

Fan Zhang, Yu‐Chen Fan

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 142, P. 113107 - 113107

Published: Sept. 13, 2024

Language: Английский

Citations

4
ATOH8 confers the vulnerability of tumor cells to ferroptosis by repressing SCD expression DOI
Huixiang Xiao, Xinxing Du, Huan Hou

et al.

Cell Death and Differentiation, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

Language: Английский

Citations

0
HSPB1/KDM1 A facilitates ANXA2 expression via hypomethylated DNA promoter to inhibit ferroptosis and enhance gemcitabine resistance in pancreatic cancer DOI

Liuxu Yang,

Ruizhe Wang, Lun Zhang

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: May 14, 2025

Language: Английский

Citations

0
A novel ferroptosis-related signature for predicting prognosis, immune characteristics, and treatment prediction in hepatocellular carcinoma DOI Creative Commons

C. Wu,

Xinyuan Chen, Yu Zhang

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(6), P. e0322158 - e0322158

Published: June 4, 2025

Hepatocellular carcinoma (HCC) is a malignant tumor with high incidence and fatality. The occurrence progression of HCC are tightly linked to ferroptosis, unique type cell death. To accurately predict the prognosis, immunological traits, treatment sensitivity, drug prediction for patients HCC, this work attempts develop novel ferroptosis-related gene signature (nFRGs). Several machine learning techniques were applied build nFRGs model utilizing data from Cancer Genome Atlas (TCGA) GSE14520 datasets. Different analysis packages in R version 4.4.1 also used prognosis analysis, molecular function somatic mutation immunotherapy response evaluation, sensitivity compare differences between low-risk high-risk groups. includes five genes (KIF20A, NT5DC2, G6PD, SLC7A11, EZH2). results indicate that an independent prognostic risk factor patients, group have worse prognosis. Our shows better accuracy reliability predicting than other existing models. Both high- groups had differentially expressed (DEGs) enriched pathways mostly associated traits progression. exhibited clear immune escape characteristics, significant upregulation expression checkpoints TIDE scores. Furthermore, IPS revealed less responsive immunotherapy, while showed potential therapy response, which further highlights as predictor outcomes. This suggests stronger suppression status potentially leading poorer checkpoint inhibitors (ICIs). In contrast, displayed lower features, making them more susceptible responses. Additionally, there mutations, functions, factors Lastly, our investigation predicted possible medications would well found sensitive chemotherapeutic targeted both conclusion, could serve biomarker, providing valuable insights personalized strategies.

Language: Английский

Citations

0